Children's Mercy Kansas City, Kansas City, Missouri, USA.
University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA.
Clin Transl Sci. 2023 Aug;16(8):1294-1308. doi: 10.1111/cts.13546. Epub 2023 Jun 2.
Allergic conditions, such as asthma, chronic urticaria, atopic dermatitis (AD), and eosinophilic esophagitis, have long been treated with oral and topical steroids which resulted in negative off-target effects. However, newer biologic medications are increasingly being developed and approved for treatment of these conditions. These medications have a variety of mechanisms of action to target pathophysiology specific to these diseases. As biologics become more targeted, fewer off-target effects are seen improving tolerability for patients as well as expanded options for treatment of these conditions. This review discusses monoclonal antibody therapies (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, and tralokinumab) including their safety and use in asthma, chronic urticaria, AD, and eosinophilic esophagitis.
过敏症，如哮喘、慢性荨麻疹、特应性皮炎（AD）和嗜酸性食管炎，长期以来一直采用口服和局部类固醇治疗，但会产生负面的非靶标效应。然而，越来越多的新型生物药物被开发和批准用于这些疾病的治疗。这些药物具有多种作用机制，可针对这些疾病的特定病理生理学进行靶向治疗。随着生物制剂变得更具针对性，非靶标效应减少，患者的耐受性提高，同时为这些疾病的治疗提供了更多选择。本文综述了单克隆抗体疗法（奥马珠单抗、美泊利单抗、瑞利珠单抗、贝那利珠单抗、度普利尤单抗、特泽单抗和曲罗替尼），包括它们在哮喘、慢性荨麻疹、AD 和嗜酸性食管炎中的安全性和应用。
